[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100395157":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":34,"studyPopulation":35,"armGroups":36,"interventions":42,"overallOfficials":30,"centralContacts":47,"locations":57,"responsibleParty":161,"collaborators":30,"id":163,"slug":164,"hasResults":165,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":165,"sex":170,"minAge":30,"maxAge":171,"enrollmentInfo":172,"targetDuration":30,"studyType":44,"phases":30,"briefSummary":175,"conditions":176,"keywords":30,"overallStatus":60,"whyStopped":30,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":187},{"fullName":5,"class":6},"French Africa Pediatric Oncology Group","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":26,"otherOutcomes":30},[9,13,17,20,23],{"measure":10,"description":11,"timeFrame":12},"Evaluation of the number of cases with local disease.","evaluating the initial clinical reports and later histological reports to confirm the diagnosis and the stage.","5 years",{"measure":14,"description":15,"timeFrame":16},"Evaluation of the number of cases by stage at the time of diagnosis.","evaluating the initial clinical reports and later histological reports to confirm the stage and the diagnosis.","5 Years",{"measure":18,"description":19,"timeFrame":16},"Evaluating the treatment given.","Comparison of treatment given and recommended treatment.",{"measure":21,"description":22,"timeFrame":16},"Evaluating the follow up after treatment.","How many children alive or dead after treatment",{"measure":24,"description":25,"timeFrame":12},"Number of relapse cases","The evaluation and the treatment of relapse and outcome",[27],{"measure":28,"description":29,"timeFrame":12},"Application of therapeutic recommendations","Evaluations of the correct application of recommendations",null,{"allocation":30,"interventionModel":30,"interventionModelDescription":30,"primaryPurpose":30,"observationalModel":32,"timePerspective":33,"maskingInfo":30},"COHORT","PROSPECTIVE","This is the 4th Burkitt's Lymphoma (LMB) study by the GFAOP group. This study hopes to include at least 14 Sub Saharian countries some of whom have never participated in a LMB study. The evaluation of improvement in early diagnosis should be possible in this study. The study hopes to be able to evaluate children earlier, with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for children with a stage IV disease. Starting from 2026 we now have the possibility of introducing rituximab into the treatment of African children with Burkitt lymphoma, starting from 15\u002F03\u002F2026. This amendment will prospectively evaluate the toxicity and effectiveness of adding rituximab to the current therapeutic recommendations. These results will be compared with those observed during the first years of implementation in two GFAOP units: specifically, the unit at CHU Yalgado Ouagadougou in Burkina Faso and CHU Treichville in Abidjan, Ivory Coast.","All Children with a Burkitt's Lymhoma.",[37],{"label":38,"type":30,"description":39,"interventionNames":40},"All children with Burkitt lymphoma and in 2 units the addition of Rituximab","An amendment has been added to give 4 injections during induction treatments as in the study in adults, that is to say 1 injection on D1 and D6 of each induction treatment, COPM or COPADM depending on the risk group in two centers. It is an amendment of the therapeutic recommendations \"GFA LMB2019\" which are the basis, the other centers will continue with this GFALMB2019 protocol as is",[41],"Other: OBSERVATIONAL",[43],{"type":6,"name":44,"description":45,"armGroupLabels":46,"otherNames":30},"OBSERVATIONAL","OBSERVAITON OF THE CAPACITY OF THE GROUP TO TREAT ACCORDING TO THE PROTOCOLE AND LOOK AT OUTCOME FOR STAGE I AND II DISEASE",[38],[48,53],{"name":49,"role":50,"phone":51,"phoneExt":30,"email":52},"Chantal Ms BOUDA, Dr.","CONTACT","00(226)70 10 01 30","cgbouda@yahoo.fr",{"name":54,"role":50,"phone":55,"phoneExt":30,"email":56},"BRENDA MALLON, MSc PhD","0033142115411","brenda.mallon@gustaveroussy.fr",[58,74,87,102,116,131,146],{"facility":59,"status":60,"city":61,"state":30,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Hopital Yalgado Ouedraogo","RECRUITING","Ouagadougou","03 BP 7022","Burkina Faso","BF",{"type":66,"coordinates":67},"Point",[68,69],-1.53388,12.36566,{"lat":69,"lon":68},[72],{"name":73,"role":50,"phone":30,"phoneExt":30,"email":30},"BOUDA CHANTAL, DR",{"facility":75,"status":60,"city":76,"state":30,"zip":30,"country":77,"countryCode":30,"cosmosGeoPoint":78,"geoPoint":82,"contacts":83},"CHU de Treichville à ABIDJAN","Abidjan","Côte d’Ivoire",{"type":66,"coordinates":79},[80,81],-4.00167,5.35444,{"lat":81,"lon":80},[84],{"name":85,"role":50,"phone":30,"phoneExt":30,"email":86},"Line Dr COUITCHERE, MD","line.couitchere@gfaop.org",{"facility":88,"status":60,"city":89,"state":90,"zip":91,"country":92,"countryCode":93,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Cliniques Universitaires de Kinshasa","Kinshasa","Kinshasa City","BP 12 KIN XI","Democratic Republic of the Congo","CD",{"type":66,"coordinates":95},[96,97],15.31357,-4.32758,{"lat":97,"lon":96},[100],{"name":101,"role":50,"phone":30,"phoneExt":30,"email":30},"BUDIONGO Aléine, DR",{"facility":103,"status":60,"city":104,"state":30,"zip":105,"country":92,"countryCode":93,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"Cliniques Universitaires de Lubumbashi (CUL)","Lubumbashi","BP 1825",{"type":66,"coordinates":107},[108,109],27.47938,-11.66089,{"lat":109,"lon":108},[112],{"name":113,"role":50,"phone":114,"phoneExt":30,"email":115},"LUKAMBA Robert, DR","00(243) 814024633","robertlukamba@yahoo.fr",{"facility":117,"status":60,"city":118,"state":30,"zip":119,"country":120,"countryCode":121,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"HJRA, Hôpital universitaire Joseph Ravoahangy Andrianavalona","Antananarivo","BP 4150","Madagascar","MG",{"type":66,"coordinates":123},[124,125],47.53613,-18.91368,{"lat":125,"lon":124},[128],{"name":129,"role":50,"phone":130,"phoneExt":30,"email":30},"Mbolanirina RAKOTOMAHEFA, Dr","34 14 201 51",{"facility":132,"status":60,"city":133,"state":30,"zip":30,"country":134,"countryCode":135,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"CHU Gabriel Touré (HGT)","Bamako","Mali","ML",{"type":66,"coordinates":137},[138,139],-7.97522,12.60915,{"lat":139,"lon":138},[142],{"name":143,"role":50,"phone":144,"phoneExt":30,"email":145},"BOUBACAR TOGO, PROFESSEUR","+223 66 74 29 04","boubacar.togo@gfaop.org",{"facility":147,"status":60,"city":148,"state":30,"zip":149,"country":150,"countryCode":151,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Hôpital Aristide Le Dantec","Dakar","BP 3001","Senegal","SN",{"type":66,"coordinates":153},[154,155],-17.44406,14.6937,{"lat":155,"lon":154},[158],{"name":159,"role":50,"phone":160,"phoneExt":30,"email":30},"Fatou-Binetou DIAGNE AKONDE, Dr","00(221)77 637 40 63",{"type":162,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100395157","recommendations-for-the-treatment-of-children-with-burkitts-lymphoma-100395157",false,"NCT04425421","Recommendations for the Treatment of Children With Burkitt's Lymphoma","GFALMB2019","Inclusion Criteria:\n\nClinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment.\n\n\\-\n\nExclusion Criteria:\n\nNot a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal.","ALL","18 Years",{"count":173,"type":174},1000,"ESTIMATED","This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.",[177],"Burkitt Lymphoma","2026-02-27",{"date":180,"type":181},"2026-03-02","ACTUAL",{"date":183,"type":181},"2020-11-01",{"date":185,"type":174},"2030-12-31",{"name":5,"class":6},7]